C&EN journal has just published a very interesting article about how new drugs pull continuous process manufacturing into the batch-dominated world of pharmaceutical.
In this interesting report by Rick Mullin is stated that “while most industries have employed continuous manufacturing processes for decades, if not centuries, the pharmaceutical industry has remained staunchly committed to batch operations. Drugmakers have steered clear of making major changes to validated processes, despite the advantages to be gained in cost, process time, and quality. But new drugs coming to market—chemically complex and targeted therapies—call for just the benefits that continuous processes offer. With the US Food and Drug Administration’s blessing, drug companies are finally implementing technologies that have been in development for 20 years”.
You will find the full article here.